{"id":37519,"date":"2016-08-04T05:46:39","date_gmt":"2016-08-04T09:46:39","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=37519"},"modified":"2016-08-04T05:46:39","modified_gmt":"2016-08-04T09:46:39","slug":"inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519","title":{"rendered":"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching"},"content":{"rendered":"<p><strong>Inovio Pharmaceuticals, Inc. (NASDAQ:INO)<\/strong> has revealed on Wednesday that it will continue to independently develop INO-1800, a hepatitis B DNA immunotherapy, after Roche Holding Ltd. (OTCMKTS:RHHBY) decided to entirely discontinue collaborating with the company.<\/p>\n<p><strong>Inovio\u2019s Plans for INO-1800 Development<\/strong><\/p>\n<p>The company will proceed with the randomized, open-label, active-controlled Phase I clinical trial of INO-1800 in 30 clinical sites in the US and Asia-Pacific, with enrollment expected to be completed by the first half of 2017. The study aims to evaluate the immunogenicity, safety, and tolerability of INO-1800 and its combination with INO-9112, an IL-12-based immune activator in adults with chronic hepatitis B infection. Meanwhile, secondary endpoints include the cellular and humoral immune response to INO-1800 and the effects on different antiviral and viral parameters.<\/p>\n<p>Dr. Joseph Kim, Inovio Pharmaceuticals CEO and President, expressed in behalf of the company that he is confident about the potentials of INO-1800. Interim results of the clinical trial, specifically, have demonstrated the potential of the immunotherapy to treat chronic hepatitis B infection.<\/p>\n<p>All licenses granted to Roche back in 2013 relating to INO-1800 will be returned to Inovio Pharmaceuticals.<\/p>\n<p><strong>Chronic Hepatitis B<\/strong><\/p>\n<p>Chronic hepatitis B infection is currently one of the primary causes of liver cancer and liver cirrhosis, affecting more than 240 million individuals globally. Over 60 million of these individuals are at risk for serious liver cancer and liver cirrhosis complications.<\/p>\n<p><strong>Phase I Clinical Trial of GLS-5700<\/strong><\/p>\n<p>Last week, Inovio Pharmaceuticals has announced the dosing of the first participant in the Phase I clinical trial evaluating GLS-5700 for the treatment pf Zika DNA virus. Currently, the open-label Phase I clinical trial is already approved by the US Food and Drug Administration (FDA) and Health Canada\u2014 Health Products and Food Branch.<\/p>\n<p>The study involves 40 healthy adult participants. It has a primary endpoint of determining the immunogenicity, safety, and tolerability of GLS-5700 administered with CELLECTRA-3P, a proprietary intradermal DNA delivery platform.<\/p>\n<p>According to the US Centers for Disease Control (CDC), about 30 million to 40 million individuals from the US travel to areas affected by the Zika virus every year. As a result, there is a growing need for a Zika vaccine to counter the harmful effects to public health.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has revealed on Wednesday that it will continue to independently develop INO-1800, a hepatitis B DNA immunotherapy, after Roche Holding Ltd. [&hellip;]<\/p>\n","protected":false},"author":32,"featured_media":16238,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[6896,9714,12060,9715],"stock_ticker":[],"class_list":["post-37519","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-inovio-pharmaceuticals-inc","tag-inovio-pharmaceuticals-inc-nasdaqino","tag-joseph-kim","tag-nasdaqino","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has revealed on Wednesday that it will continue to independently develop INO-1800, a hepatitis B DNA immunotherapy, after Roche Holding Ltd. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2016-08-04T09:46:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2250\" \/>\n\t<meta property=\"og:image:height\" content=\"840\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Greg Folin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Greg Folin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519\"},\"author\":{\"name\":\"Greg Folin\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\"},\"headline\":\"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching\",\"datePublished\":\"2016-08-04T09:46:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519\"},\"wordCount\":379,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg\",\"keywords\":[\"Inovio Pharmaceuticals Inc\",\"Inovio Pharmaceuticals Inc (NASDAQ:INO)\",\"Joseph Kim\",\"NASDAQ:INO\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519\",\"name\":\"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg\",\"datePublished\":\"2016-08-04T09:46:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg\",\"width\":2250,\"height\":840},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e\",\"name\":\"Greg Folin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg\",\"caption\":\"Greg Folin\"},\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519","og_locale":"en_US","og_type":"article","og_title":"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching - Wall Street PR","og_description":"Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has revealed on Wednesday that it will continue to independently develop INO-1800, a hepatitis B DNA immunotherapy, after Roche Holding Ltd. [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2016-08-04T09:46:39+00:00","og_image":[{"width":2250,"height":840,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg","type":"image\/jpeg"}],"author":"Greg Folin","twitter_misc":{"Written by":"Greg Folin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519"},"author":{"name":"Greg Folin","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e"},"headline":"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching","datePublished":"2016-08-04T09:46:39+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519"},"wordCount":379,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg","keywords":["Inovio Pharmaceuticals Inc","Inovio Pharmaceuticals Inc (NASDAQ:INO)","Joseph Kim","NASDAQ:INO"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519","url":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519","name":"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg","datePublished":"2016-08-04T09:46:39+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/02\/inovio_logo.jpg","width":2250,"height":840},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/inovio-pharmaceuticals-inc-nasdaqino-to-continue-ino-1800-development-amid-roche-holding-ltd-otcmktsrhhby-ditching-37519#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Inovio Pharmaceuticals, Inc. (NASDAQ:INO), To Continue INO-1800 Development Amid Roche Holding Ltd. (OTCMKTS:RHHBY) Ditching"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/09a8586a8976289812879bbc81ac988e","name":"Greg Folin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2020\/05\/4w1JQvu5_400x400-300x300.jpg","caption":"Greg Folin"},"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/greg-folin"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37519","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/32"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=37519"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/37519\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/16238"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=37519"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=37519"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=37519"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=37519"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}